Autoimmune thyroiditis in non-obese subjects with initial diagnosis of Type 2 diabetes mellitus
Language English Country Italy Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
12398236
DOI
10.1007/bf03345512
PII: 5835
Knihovny.cz E-resources
- MeSH
- Thyroiditis, Autoimmune complications epidemiology MeSH
- Autoantibodies analysis MeSH
- C-Peptide blood MeSH
- Diabetes Mellitus, Type 2 complications diet therapy drug therapy MeSH
- Adult MeSH
- Glutamate Dehydrogenase immunology MeSH
- Hypoglycemic Agents therapeutic use MeSH
- Incidence MeSH
- Insulin therapeutic use MeSH
- Middle Aged MeSH
- Humans MeSH
- Postprandial Period MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Autoantibodies MeSH
- C-Peptide MeSH
- Glutamate Dehydrogenase MeSH
- Hypoglycemic Agents MeSH
- Insulin MeSH
Autoimmune thyroiditis is often associated with Type 1 diabetes mellitus (T1DM). In non-obese adult-onset diabetes diagnosed initially as Type 2 diabetes mellitus (T2DM), there is a proportion of cases with so far undiagnosed T1DM. The objective of this study was to estimate the frequency of autoimmune thyroiditis (AT) among non-obese (BMI <30.0 kg/m2) patients with T2DM and to compare the frequency of AT in subgroups of patients according to the presence of glutamic acid decarboxylase antibodies (GADA), insulin requirement, and post-breakfast C-peptide levels. The study included 118 adult patients (55 men and 63 women) with the initial diagnosis of T2DM and age at the onset of diabetes > 35 yr. Median of age was 66 yr (range 39-82), and median duration of diabetes was 9 (range 1-27) yr. AT was diagnosed using thyroid peroxidase antibodies, TG-antibodies, US and TSH levels. Nineteen per cent of the subjects were found to have AT, and the frequency of AT did not significantly differ between the groups of GADA+ and GADA- subjects. There was no difference in the frequency of AT between the group treated with hypoglycemic agents and/or diet and the group requiring insulin. The frequency of AT was higher in the group with post-breakfast C-peptide levels < or = 0.8 nmol/l compared to the group with post-breakfast C-peptide levels > 0.8 nmol/l (37% vs 16%), however the group with post-breakfast C-peptide levels < or = 0.8 nmol/l had longer duration of diabetes.
See more in PubMed
Am J Clin Pathol. 1994 Jun;101(6):698-702 PubMed
Eur J Endocrinol. 1999 Jun;140(6):512-8 PubMed
Diabetes Care. 1999 Mar;22 Suppl 2:B59-64 PubMed
Diabetes. 1982 Feb;31(2):122-5 PubMed
Thyroid. 2000 Mar;10 (3):251-9 PubMed
Diabetes. 1988 Jan;37(1):99-103 PubMed
J Pediatr Endocrinol Metab. 1996 Mar;9 Suppl 1:89-94 PubMed
Diabetes Care. 1997 Jul;20(7):1183-97 PubMed
J Pathol. 1991 Mar;163(3):257-64 PubMed
Diabetes Care. 1999 Mar;22(3):377-81 PubMed
Baillieres Clin Endocrinol Metab. 1997 Jul;11(2):251-70 PubMed
Diabetes. 1999 Jan;48(1):150-7 PubMed
Acta Diabetol. 1995 Jun;32(2):121-4 PubMed
Vnitr Lek. 1996 Nov;42(11):767-71 PubMed
Exp Clin Endocrinol Diabetes. 1995;103(2):123-5 PubMed
Diabetes. 1993 Feb;42(2):359-62 PubMed
Clin Endocrinol (Oxf). 2000 May;52(5):565-73 PubMed
Diabet Med. 1994 Apr;11(3):299-303 PubMed
Diabet Med. 1996 May;13(5):415-9 PubMed
Horm Res. 1999;52(3):113-8 PubMed
J Clin Endocrinol Metab. 1998 May;83(5):1548-51 PubMed
Dtsch Med Wochenschr. 1999 Dec 10;124(49):1476-81 PubMed
J Endocrinol Invest. 1991 Feb;14 (2):115-21 PubMed
Diabetes Care. 1995 Dec;18(12):1557-65 PubMed
Acta Endocrinol (Copenh). 1990 Nov;123(5):493-8 PubMed
